SciSparc (SPRC) Stock Price, News & Analysis

Company Overview

SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based specialty pharmaceutical company focused on developing therapies that combine cannabinoids with other pharmaceutical compounds. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including neurological and central nervous system disorders.

SciSparc has developed a pipeline that has included SCI-110, an investigational cannabinoid-based treatment being studied for conditions such as Tourette syndrome and Alzheimer’s disease-related agitation, and SCI-210, a combination therapy under development for autism spectrum disorder. The company has also pursued research into cannabinoid-based treatments for pain and other medical conditions. These products remain investigational and are subject to clinical and regulatory requirements.

The company was formerly known as Therapix Biosciences Ltd. and adopted the SciSparc name as part of a strategic repositioning of its business. SciSparc is headquartered in Israel and conducts its activities through research, clinical development and collaborations with academic and medical institutions. Its management has included Chief Executive Officer Oz Adler.

Key Stats

• Today's Range: $4.64 to $4.64
• 50-Day Range: $4.27 to $9.09
• 52-Week Range: $2.98 to $80.10
• Volume: 998 shs
• Average Volume: 497,522 shs
• Market Capitalization: $2.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

SciSparc Stock Analysis - MarketRank™

SciSparc scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

SciSparc has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

SciSparc has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SciSparc has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.78% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 10.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SciSparc does not currently pay a dividend.

Dividend Growth

SciSparc does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for SPRC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SciSparc insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.52% of the stock of SciSparc is held by insiders.

Percentage Held by Institutions

25.06% of the stock of SciSparc is held by institutions.

Company Calendar

• Today: 9/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SPRC
• CIK: 1611746
• Web: scisparc.com
• Phone: 972-3717-5777
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 2.38

Sales & Book Value

• Annual Sales: $856 thousand
• Price / Sales: 3.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.93 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 566,000
• Free Float: 557,000
• Market Cap: $2.61 million
• Optionable: Not Optionable
• Beta: 2.81